<DOC>
	<DOC>NCT00378833</DOC>
	<brief_summary>This is a 16-week clinical trial in lipid clinic patients for whom niacin therapy is appropriate to evaluate the tolerability of MK0524A versus niacin extended-release. There will be 6 scheduled clinic visits and 2 treatment groups.</brief_summary>
	<brief_title>Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Patient is an appropriate candidate for niacin therapy (at risk for heart disease) and triglycerides &lt; 500 mg/dL Patients with a history of any cardiovascular event directly linked to atherosclerosis with a low density lipoproteincholesterol (LDLC) &gt;/= 130 mg/dL and/or not on a statin Patients with diabetes and LDLC &gt;/= 130 mg/dL. Patients with &gt;/= 2 heart disease risk factors and LDLC &gt;/= 160 mg/dL. Patients who have had a cardiovascular event (e.g., heart attack, stroke) within the previous 3 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primary Hypercholesterolemia or Mixed Hyperlipidemia</keyword>
</DOC>